成人起病与老年起病炎症性肠病的死亡率:1964-2014年全国性登记队列研究
基于瑞典1964-2014年全国登记数据,比较82 718例新发炎症性肠病(IBD)患者与801 180名匹配参照个体的死亡率。IBD患者全因死亡风险升高(HR=1.5;95%CI 1.5至1.5),老年起病IBD同样升高(HR=1.5;95%CI 1.5至1.5),溃疡性结肠炎、克罗恩病和未分型IBD均升高,且随时间推移相对死亡率下降。
要点
- IBD患者全因死亡风险为参照个体的1.5倍(HR=1.5;95%CI 1.5至1.5)。
- 老年起病IBD(≥60岁)全因死亡风险同样升高(HR=1.5;95%CI 1.5至1.5)。
- 消化系统疾病死亡风险升高最明显(HR=5.2;95%CI 4.9至5.5)。
核心结论
- 成人起病和老年起病的溃疡性结肠炎、克罗恩病及未分型IBD患者均有死亡风险升高。
- 生物制剂引入后死亡风险仍升高,但随时间推移已下降。
研究设计与样本
- 瑞典1964-2014年全国性登记队列研究,纳入82 718例新发IBD病例(住院和非基层门诊诊疗),按1:10匹配801 180名一般人群参照个体,采用多因素Cox回归估计HR。
- IBD患者中老年起病(≥60岁)者17 873例。
主要发现
- 随访984 330人年期间,IBD患者死亡15 698/82 718例(19%,15.9/1000人年),参照个体死亡121 095/801 180例(15.1%),对应IBD的HR=1.5(95%CI 1.5至1.5),即每年每263例患者多1例死亡。
- 溃疡性结肠炎死亡风险升高(HR=1.4;95%CI 1.4至1.5),克罗恩病升高(HR=1.6;95%CI 1.6至1.7),未分型IBD升高(HR=1.6;95%CI 1.5至1.8)。
- IBD与多种死因死亡率升高相关,其中心血管疾病HR=1.3(95%CI 1.3至1.3),恶性肿瘤HR=1.4(95%CI 1.4至1.5),消化系统疾病HR=5.2(95%CI 4.9至5.5)。
- 随访前5年的相对死亡率随时间推移显著下降。
- 2002-2014年新发病例的平均估计寿命较匹配参照个体短2.3年。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine all-cause and cause-specific mortality in adult-onset and elderly-onset IBD and to describe time trends in mortality over the past 50 years. DESIGN: Swedish nationwide register-based cohort study 1964-2014, comparing mortality in 82 718 incident IBD cases (inpatient and non-primary outpatient care) with 10 times as many matched general population reference individuals (n=801 180) using multivariable Cox regression to estimate HRs. Among patients with IBD, the number of participants with elderly-onset (≥60 years) IBD was 17 873. RESULTS: During 984 330 person-years of follow-up, 15 698/82 718 (19%) of all patients with IBD died (15.9/1000 person-years) compared with 121 095/801 180 (15.1%) of reference individuals, corresponding to an HR of 1.5 for IBD (95% CI=1.5 to 1.5 (HR=1.5; 95% CI=1.5 to 1.5 in elderly-onset IBD)) or one extra death each year per 263 patients. Mortality was increased specifically for UC (HR=1.4; 95% CI=1.4 to 1.5), Crohn's disease (HR=1.6; 95% CI=1.6 to 1.7) and IBD-unclasssified (HR=1.6; 95% CI=1.5 to 1.8). IBD was linked to increased rates of multiple causes of death, including cardiovascular disease (HR=1.3; 1.3 to 1.3), malignancy (HR=1.4; 1.4 to 1.5) and digestive disease (HR=5.2; 95% CI=4.9 to 5.5). Relative mortality during the first 5 years of follow-up decreased significantly over time. Incident cases of 2002-2014 had 2.3 years shorter mean estimated life span than matched comparators. CONCLUSIONS: Adult-onset and elderly-onset patients with UC, Crohn's disease and IBD-unclassified were all at increased risk of death. The increased mortality remained also after the introduction of biological therapies but has decreased over time.
引用
- Olén O, Askling J, Sachs MC, et al. Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964-2014. Gut. 2019. PMID: 31092591. doi:10.1136/gutjnl-2018-317572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。